Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Erlotinib With Docetaxel Versus Docetaxel Alone in Second Line NSCLC
NCT01350817Phase 2Completed
- Sponsor
- CHU de Limoges
- Start
- Jun 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by CHU de Limoges. Primary endpoint: Progression Free Survival at 15 weeks. Started Jun 2011; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01350817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01350817.